MDNAF - Medicenna Therapeutics Corp.

$0.82

0.09

(+12.33%)

Pre-Market: $0.82

0.00

(%)

Medicenna Therapeutics :MDNAF Medicenna is a clinical stage immunotherapy company that engineers novel, powerful and proprietary interleukins we call Superkines. Leveraging our Superkine Platform, we are able to modulate, fine-tune or amplify the immune system to tackle the most challenging diseases, including a broad range of cancers with tremendous unmet need.

Location: Toronto, Canada | Website: https://www.medicenna.com/ | Industry: | Sector:

Market Cap

64.14M

52 Wk Range

$0.60 - $2.20

Previous Close

$0.73

Open

$0.80

Day Range

$0.80 - 0.85

Volume

19,320

Avg Volume

59,465

Enterprise Value

34.31M

Cash

30.0M

Avg Qtr Burn

-4.085M

Short % of Float

0.22%

Insider Ownership

22.14%

Institutional Own.

12.83%

Qtr Updated

12/31/24

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
MDNA55 (Bizaxofusp) Details Glioblastoma, Cancer	Phase 2b Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
MDNA11 (IL-2) Details Cancer, Cold tumors	Phase 1/2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.